CD19 and diffuse large B-cell lymphoma: Tu et al. [15] reported satisfactory clinical prognosis and controllable adverse events in a r/r primary CNS diffuse large-cell lymphoma (DLBCL) patient who received CD19/70 CAR T-cell infusion, indicating that CNSL was no longer an absolute contraindication for CAR T-cell immunotherapy.